Likewise, as demonstrated here, not only drugs targeting the VEGF axis can overcome tumor endothelial cell anergy, also drugs targeting epithelial growth factor receptor (EGFR, erlotinib) and platelet derived growth factor receptor (PDGFR, crenolanib) can normalize ICAM-1 expression. The gene discussed is EGFR; the disease is neoplasm.